阿松德西安与CYP3A和P-gp抑制剂或诱导剂联用的药代动力学:体外与体内目标研究
阿松德西安是口服直接可逆性活化因子XI(FXIa)抑制剂。体外研究显示其主要由羧酸酯酶1代谢,次要经CYP3A4代谢,且为P-gp底物。健康男性参与者中,P-gp与强或中效CYP3A4联合抑制使AUC分别增加103%和75.6%,单纯中效CYP3A4抑制无影响;卡马西平联合诱导使AUC降低44.4%。药效呈浓度依赖性,安全耐受良好。
要点
- 阿松德西安主要经羧酸酯酶1代谢,CYP3A4和P-gp也参与其处置。
- P-gp与强CYP3A4联合抑制使阿松德西安AUC增加103%,与中效CYP3A4联合抑制增加75.6%。
- 卡马西平联合诱导P-gp和CYP3A4使阿松德西安AUC降低44.4%。
核心结论
- CYP3A4和P-gp参与阿松德西安的代谢与排泄,联合抑制或诱导可显著改变其暴露量。
研究设计与样本
- 体外研究考察阿松德西安对多种CYP同工酶、水解酶和药物转运体的底物特征。
- 健康男性参与者中开展1期研究,考察联用P-gp和CYP3A4抑制剂(伊曲康唑、维拉帕米或氟康唑)或诱导剂(卡马西平)后的药代动力学。
主要发现
- 阿松德西安主要经羧酸酯酶1代谢,次要经CYP3A4代谢,且为P-gp底物。
- P-gp与强CYP3A4联合抑制时阿松德西安AUC增加103%,与中效CYP3A4联合抑制时增加75.6%。
- 单纯中效CYP3A4抑制对阿松德西安AUC无影响。
- 卡马西平联合诱导P-gp和CYP3A4使阿松德西安AUC降低44.4%。
- 药效标志物(活化部分凝血活酶时间和FXIa抑制)呈浓度依赖性,最大效应和恢复未见与PK效应相关的差异。
关键数值与推荐
- 阿松德西安AUC在P-gp与强CYP3A4联合抑制时增加103%。
- 阿松德西安AUC在P-gp与中效CYP3A4联合抑制时增加75.6%。
- 阿松德西安AUC在卡马西平联合诱导P-gp和CYP3A4时降低44.4%。
临床怎么用
- 临床联用P-gp与CYP3A4强或中效抑制剂时需关注阿松德西安暴露量升高。
- 联用P-gp和CYP3A4诱导剂(如卡马西平)时需关注阿松德西安暴露量降低。
局限性
- 1期研究仅在健康男性参与者中进行。
- 药效学差异未随PK变化观察到,但未报告临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Asundexian is an oral, direct and reversible inhibitor of activated factor XI (FXIa) in development for the treatment of thromboembolic events. This article summarizes results from preclinical and clinical studies, including identification of enzymes involved in asundexian pharmacokinetics, and evaluation of potential target drug-drug interactions. METHODS: In vitro studies investigated the substrate characteristics of asundexian towards several cytochrome P450 (CYP) isoforms, hydrolytic enzymes and drug transporters. Inhibition of the amide hydrolysis of asundexian was investigated in vitro for several relevant drugs. Phase 1 studies in healthy male participants investigated the pharmacokinetics (PK) of asundexian upon co-administration of combined inhibitors or an inducer of P-gp and CYP3A4 (itraconazole, verapamil or carbamazepine, respectively, or the moderate CYP3A4 inhibitor fluconazole). The pharmacodynamic (PD) markers are activated partial thromboplastin time and FXIa inhibition. RESULTS: Asundexian was predominantly metabolized via carboxylesterase 1 and, to a lesser extent, via CYP3A4 and is a substrate of P-gp. The asundexian area under the plasma concentration-time curve (AUC) increased by 103% and 75.6% upon combined inhibition of P-gp and strong or moderate inhibition of CYP3A4, respectively, but was unaffected by moderate CYP3A4 inhibition. Combined P-gp and CYP3A4 induction by carbamazepine decreased asundexian AUC by 44.4%. PD is concentration-dependent, thus no differences in maximum responses and recovery commensurate with PK effect(s) were observed. Adverse events were mild and asundexian was well tolerated. CONCLUSIONS: The presented studies confirmed that CYP3A4 and P-gp contribute to asundexian metabolism and excretion. Observed effects were in line with data from a previous mass balance study.
引用
- Kanefendt F, Brase C, Jungmann N, et al. Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: Target in vitro and in vivo studies. Br J Clin Pharmacol. 2024. PMID: 38048692. doi:10.1111/bcp.15981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。